MedTrace Logo

Safety of Genexol PM and Carboplatin as First-line Therapy in Ovarian Cancer

NCT05300828 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2023-06-26

No results posted yet for this study

Summary

To evaluate the safety profile of Genexol PM combination with carboplatin for patients with newly diagnosed ovarian cancer. We hypothesized Genexol PM can be safely administered to newly diagnosed ovarian cancer patients compared to conventional paclitaxel/carboplatin combination therapy. Therefore, we will compare the prospective cohort with a historical comparison with patients administered paclitaxel/carboplatin and paclitaxel/carboplatin/bevacizumab combination therapy.

Conditions

Interventions

DRUG

Genexl PM

Every three weeks, after intravenous infusion of 260 mg/m2 for 3 hours, followed by carboplatin AUC 5 for 3 hours.

Sponsors & Collaborators

  • Samyang Biopharmaceuticals Corporation

    collaborator INDUSTRY

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Hee Seung Kim · Seoul National University Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-19
Primary Completion
2022-04-30
Completion
2022-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05300828 on ClinicalTrials.gov